BOSTON — In this Healio Video Perspective from the ASCRS meeting, Darrell E. White, MD, discusses positive patient comfort results with Miebo from the phase 3 MOJAVE and GOBI trials.
Approximately 1,200 patients with dry eye disease received Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) or hypotonic saline in the clinical trials.
“In both studies, Miebo was found to be comfortable or extremely comfortable, acceptable or very acceptable, in comparison with the control,” he said.